Welcome to our dedicated page for CONCENTRA GROUP HOLDINGS PAREN SEC filings (Ticker: CON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Healthcare filings can feel like medical charts: dense, technical, and mission-critical. Concentra Group Holdings Parent Inc.’s disclosures weave together workers’ compensation statutes, telemedicine economics, and clinic utilization data—details investors hunt for yet rarely find quickly. If you have ever typed “Concentra Group Holdings Parent Inc. SEC filings explained simply” or searched for the next “Concentra Group Holdings Parent Inc. quarterly earnings report 10-Q filing,” you already know the challenge.
Stock Titan solves it. Our AI reads every line of the Concentra Group Holdings Parent Inc. annual report 10-K simplified, highlights segment profitability, and flags compliance risks in seconds. Need real-time alerts? We stream “Concentra Group Holdings Parent Inc. Form 4 insider transactions real-time,” so you can track executive stock transactions before the market reacts. Interactive dashboards turn pages of accounting notes into clear charts, while plain-English summaries answer the question: “What changed this quarter?”
The platform covers every filing type the moment it hits EDGAR: 10-K, 10-Q, 8-K material events explained, Form 4 insider trading transactions, and the proxy statement executive compensation breakdown. Use AI-powered summaries to compare clinic revenue trends, monitor workers’ comp claim costs, or assess telemedicine adoption—all without wading through footnotes. Whether you’re performing a Concentra Group Holdings Parent Inc. earnings report filing analysis or simply understanding Concentra Group Holdings Parent Inc. SEC documents with AI, our tools let you move from data to decision faster.
Concentra Group Holdings Parent, Inc. — Form 10-Q (Quarter ended June 30, 2025)
Q2 2025 revenue rose to $550.8 million versus $477.9 million in Q2 2024 (+~15%). Six-month revenue was $1,051.5 million versus $945.5 million. Despite revenue growth, net income attributable to the company declined to $44.6 million for the quarter (Q2 2024: $51.7 million); EPS fell to $0.35 (Q2 2024: $0.50). Cash declined to $73.9 million from $183.3 million at year-end 2024.
Material corporate actions: acquisition of Nova Medical Centers (closed March 1, 2025) for a preliminary purchase price of $265.0 million and Pivot Onsite Innovations (closed June 1, 2025) for $54.4 million. Goodwill increased materially (preliminary goodwill of $206.96M and $34.43M). Company amended credit facilities (revolver increased to $450M; incremental term loan $102.1M); net leverage was 3.8x (covenant 6.5x). AOCI shows $3.9 million loss from hedges. Significant contingencies include a multi-million patient data-breach class action matter and DOJ inquiry regarding physical therapy billing; outcomes are uncertain. Board declared a $0.0625/share dividend payable Aug 28, 2025.
Concentra Group Holdings Parent, Inc. (CON) furnished a press release and financial schedules announcing results for the quarter ended June 30, 2025 (Exhibit 99.1) and published a related presentation (Exhibit 99.2) on August 7, 2025. The filing states these items are furnished under Item 2.02 and Item 7.01 and are not "filed" for purposes of Section 18 of the Exchange Act.
Dividend: On August 6, 2025, the Board declared a cash dividend of $0.0625 per share, payable on or about August 28, 2025, to stockholders of record at the close of business on August 21, 2025. Exhibits listed in the report are 99.1 (press release), 99.2 (presentation) and 104 (Cover Page iXBRL). The report is signed by Timothy Ryan, Executive Vice President and Chief Legal Counsel, dated August 7, 2025.
Concentra Group Holdings Parent (NYSE:CON) filed an 8-K disclosing the Board’s appointment of Brigid Bonner and Vipin Gopal as independent directors, effective July 1, 2025. Bonner’s term runs to the 2027 AGM, while Gopal’s term extends to the 2026 AGM, after which each will stand for shareholder election. Compensation will follow the existing non-employee director program detailed in the 2025 proxy. The Company reported no related-party transactions or special arrangements tied to these appointments. A press release announcing the changes was furnished as Exhibit 99.1; the information was provided under Items 5.02, 7.01 and 9.01 and is deemed furnished, not filed.
FAQ
What is the current stock price of CONCENTRA GROUP HOLDINGS PAREN (CON)?
What is the market cap of CONCENTRA GROUP HOLDINGS PAREN (CON)?
